(Other OTC:CWPE),(OTC US:CWPE), Katy, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) — CW Petroleum Corp (OTCQB: CWPE) (the “Company” or “CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor Fuels, today announces to its investors and future investors Financial Results for the Six Months Ended June 30, 2025. Key Financial Highlights for Six Months Ended […]

(NASDAQ:FGEN), Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in

OXFORD, United Kingdom, Sept. 02, 2025 (GLOBE NEWSWIRE) — Sophos, a global leader of innovative security solutions for defeating cyberattacks, today announced that Sophos Endpoint is now natively integrated and automatically included in all Taegis(TM) Extended Detection and Response (XDR) and Taegis Managed Detection and Response (MDR) subscriptions. This milestone gives customers immediate access to

(NASDAQ:SEER),(NASDAQ:WGS), REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. “We are excited to welcome Isaac to our board,” said Omid Farokhzad, Chair and CEO of Seer.

(NASDAQ:NMRA), WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September. 2025 Wells

(NASDAQ:OLMA),(NYSE:PFE), Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company

(NasdaqGM:VRCA), WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment

LOS ANGELES, Sept. 02, 2025 (GLOBE NEWSWIRE) — Ampure Charging Systems (“Ampure”), a worldwide leader in vehicle charging technology backed by Transom Capital (“Transom”), is pleased to announce its acquisition of Power Designers Sibex (“Power Designers”), a leader in industrial charging products and electronics manufacturing based in Crystal River, Florida. The transaction marks a major

(TSX:PYR),(OTC US:PYRGF),(Other OTC:PYRGF),(Frankfurt:8PY1), MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces that it

(NASDAQ:AVIR), BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat at the Morgan Stanley 23rd Annual